The following article features coverage from the Society of Gynecologic Oncology’s 50th Annual Meeting on Women’s Cancer. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

Results from a multicenter, prospective cohort study of women with endometrial intraepithelial neoplasia or clinical stage I to II endometrial cancer with concomitant stress urinary incontinence prior to cancer surgery showed patient quality of life (QoL) was significantly improved in the subgroup of patients who chose to undergo concurrent stress urinary incontinence surgery compared with those who underwent cancer surgery only (P =.008). The findings from this study were presented at the Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer.

Of the 509 evaluable patients, 107 (21%) women underwent concurrent cancer and stress incontinence surgery, 96 (19%) underwent cancer surgery and non-surgical treatment of stress urinary incontinence, and 306 (60%) underwent cancer surgery alone. Less than 1% of patients had stage II endometrial cancer and 77.8% of women were diagnosed with stage I disease.

Following adjustments for confounding factors, QoL, as assessed using the Functional Assessment of Cancer Therapy—Endometrial score, increased in all treatment groups from baseline, and 6 weeks and 6 months following surgery (P <.0001 overall). Compared with cancer surgery alone, concurrent incontinence surgery was associated with a significantly higher QoL score (P =.008), but QoL score was not significantly improved when nonsurgical treatment of stress urinary incontinence with concurrent cancer surgery was compared with concurrent incontinence and cancer surgery (P =.065).

Read more of Cancer Therapy Advisor‘s coverage of SGO’s annual meeting by visiting the conference page.

Reference

  1. Robison KM, Bevis KS, Howe C, et al. Concurrent surgical treatment of urinary incontinence at the time of endometrial cancer surgery is associated with improved quality of life 6 months after cancer surgery: cancer of the uterus and treatment of incontinence (CUTI) study. Presented at: The Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer; Honolulu, Hawaii; March 16-19, 2019. Abstract 31.